Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | B2M C45W |
| Therapy | Interferon gamma |
| Indication/Tumor Type | melanoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| B2M C45W | melanoma | resistant | Interferon gamma | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line harboring B2M C45W displayed greatly reduced expression of HLA class I molecules, which was not corrected by treatment with interferon gamma (PMID: 16648140). | 16648140 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (16648140) | Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. | Full reference... |